(Total Views: 853)
Posted On: 09/21/2024 6:02:41 PM
Post# of 148870
Mild + Moderate showdown:
Lecanemabi :
"Treatment was initiated in patients with mild cognitive impairment or mild dementia stage of disease and confirmed presence of amyloid beta pathology. Patients were randomized in a 1:1 ratio to receive placebo or Leqembi at a dose of 10 milligrams (mg)/kilograms (kg), once every two weeks."
@ only 20mg's a month,
consider the SAE's
https://www.fda.gov/news-events/press-announc...l-approval
___________
Cytodyn last Letter:
"First, we are working on a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s Disease. The study will evaluate a neuroradiology primary endpoint to determine efficacy."
Lecanemabi only says Mild.
Cytodyn says Mild to Moderate.
It's known none of Lecanemabi's Mild SAE's, have ever been reported across any LL trial.
Let alone, Lecanemabi's toxicity @ mild, shows it's highly doubtful on addressing Severe Alzheimer’s.
Lecanemabi is going to be put to shame Vs Leronlimab.
My bet, very soon, same happens to Resmetirom.
Multiple trials now, Cytodyn is not dosing only @ end of life:
Glioblastoma.
Alzheimer’s
LATCH #1
LATCH #2
NASH
From my understanding, Chronic Fatigue is heavily towards brain inflammation.
Alot of data criss crossing for Cytodyn.
Every stage, of any trial type, will continue validating our ace in the whole --- Safety profile.
Outstanding.
Lecanemabi :
"Treatment was initiated in patients with mild cognitive impairment or mild dementia stage of disease and confirmed presence of amyloid beta pathology. Patients were randomized in a 1:1 ratio to receive placebo or Leqembi at a dose of 10 milligrams (mg)/kilograms (kg), once every two weeks."
@ only 20mg's a month,
consider the SAE's
https://www.fda.gov/news-events/press-announc...l-approval
___________
Cytodyn last Letter:
"First, we are working on a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s Disease. The study will evaluate a neuroradiology primary endpoint to determine efficacy."
Lecanemabi only says Mild.
Cytodyn says Mild to Moderate.
It's known none of Lecanemabi's Mild SAE's, have ever been reported across any LL trial.
Let alone, Lecanemabi's toxicity @ mild, shows it's highly doubtful on addressing Severe Alzheimer’s.
Lecanemabi is going to be put to shame Vs Leronlimab.
My bet, very soon, same happens to Resmetirom.
Multiple trials now, Cytodyn is not dosing only @ end of life:
Glioblastoma.
Alzheimer’s
LATCH #1
LATCH #2
NASH
From my understanding, Chronic Fatigue is heavily towards brain inflammation.
Alot of data criss crossing for Cytodyn.
Every stage, of any trial type, will continue validating our ace in the whole --- Safety profile.
Outstanding.
(9)
(0)Scroll down for more posts ▼
